The present study is a randomized, control, phase II study of locally advanced nasopharyngeal
carcinoma (NPC) in Northwest China treated with Gemcitabine plus cisplatin regimen (GP) or
Docetaxel plus cisplatin regimen (TP) induction chemotherapy followed by concurrent
chemoradiotherapy. The population consists of stage III-IVb nasopharyngeal carcinoma (NPC).
The effectiveness, side effects and quality of life will be evaluated according to Standard
WHO response criteria, NCI-CTC AE V3.0 and EORTC QLQ-C30 and H&N35 questionnaire.